Pulmonary infections in transplantation pathology

Archives of Pathology and Laboratory Medicine

Volumn 131, Issue 8, 2007, Pages 1219-1231

  Stewart, Susan ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; CHLAMYDOPHILA PNEUMONIAE; CYTOMEGALOVIRUS; HISTOPATHOLOGY; HUMAN; HUMAN METAPNEUMOVIRUS; IMMUNOSUPPRESSIVE TREATMENT; LEGIONELLA PNEUMOPHILA; LUNG INFECTION; LUNG TRANSPLANTATION; MORBIDITY; MORTALITY; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; MYCOPLASMA PNEUMONIAE; MYCOSIS; OPPORTUNISTIC INFECTION; PATHOLOGY; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PROPHYLAXIS; REVIEW; STEM CELL TRANSPLANTATION; VIRAL RESPIRATORY TRACT INFECTION;

HUMANS; IMMUNOCOMPROMISED HOST; INTERDISCIPLINARY COMMUNICATION; LUNG DISEASES; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; RESPIRATORY TRACT INFECTIONS; TRANSPLANTATION IMMUNOLOGY;

EID: 34547877591     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Kotloff RH, Vivek N, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2004;170:22-48.
2. Maurer JR, Tullis E, Grossman RF, Velland H, Winton TL, Patterson GA. Infectious complications following isolated Lung transplantation. Chest. 1992;101:1056-1059.
3. Cisneros JM, Munoz P, Torre-Cisneros J, et al, Spanish Transplantation Infection Study Group. Pneumonia after heart transplantation: a multi-institutional study. Clin Infect Dis. 1998;27:324-331.
4. Kramer MR, Marshall SE, Starnes VA, Gamberg P, Amita Z, Theodore J. Infectious complications in heart-lung transplantation: analysis of 200 episodes. Arch Intern Med. 1993;153:2010-2016.
5. Kusne S, Dummer JS, Singh N, et al. Infections after liver transplantation: an analysis of 101 consecutive cases. Medicine (Baltimore). 1988;67:132-143.
6. Fishman JA, Rubin RH. Infection in organ transplant recipients. N Engl J Med. 1998;338:1741-1751.
7. Weill D, Dey GC, Hicks RA, et al. A positive donor gram stain does not predict outcome following lung transplantation. J Heart Lung Transplant. 2002;21:555-558.
8. Chan KM, Allen SA. Infectious pulmonary complications in lung transplant recipients. Semin Respir Infect. 2002;17:291-302.
9. Kocher AA, Bonaros N, Dunkler D, et al. Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients. J Heart Lung Transplant. 2003;22:250-257.
10. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant. 2003;3:731-735.
11. John GT, Shankar V, Abraham AM, Mukundan U, Thomas PP, Jacob CK. Risk factors for post-transplant tuberculosis. Kidney Int. 2001;60:1148-1153.
12. Shaukat A, Faris Bakri, Young P, et al. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics. Mycopathologia. 2005;159:181-188.
13. Bag R. Fungal pneumonias in transplant recipients. Curr Opin Med. 2003;9:193-198.
14. Zihlif M, Khanchandani G, Ahmed HP, Soubani AO. Surgical lung biopsy in patients with haematological malignancy or hematopoietic stem cell transplantation and unexplained pulmonary infiltrates: improved outcome with specific diagnosis. Am J Hematol. 2005;78:94-99.
15. Lass-Florl C, Gunsilus E, Gastl G, et al. Diagnosing invasive aspergillosis during antifungal therapy by PCR analysis of blood samples. J Clin Microbiol. 2004;42:4154-4157.
16. Van Burik J-A, Myerson D, Schreckhise RW, Bowden RA. Panfungal PCR assay for detection of fungal infection in human blood specimens. J Clin Microbiol. 1998;36:1169-1175.
17. Subira M, Martino R, Rovira M, Vazquez L, Serrano D, De La Camara R. Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive Aspergillosis. Ann Hematol. 2003;82:80-82.
18. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
19. Kawazu M, Kanda Y, Goyama S, et al. Rapid diagnosis of invasive pulmonary aspergillosis by quantitative polymerase chain reaction using bronchial lavage fluid. Am J Hematol. 2003;72:27-30.
20. Zaas AK, Alexander BD. Galactomonannan and advances in fungal diagnostics. Curr Opin Organ Transplant. 2005;10:307-311.
21. Kubak BM. Fungal infection in lung transplantation. Transpl Infect Dis. 2002;4(suppl 3):24-31.
22. Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant. 2003;22:258-266.
23. Helmi M, Love RB, Welter D, Cornwell RD, Meyer KC. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest. 2003;123:800-808.
24. Cahill BC, Hibbs JR, Savik K, et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest. 1997;112:1160-1164.
25. Mehrad B, Paciocco G, Martinez FJ, Ojo TC, Iannettoni MD, Lynch JP III. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest. 2001;119:169-175.
26. Sharma OP, Chwogule R. Many faces of pulmonary Aspergillosis. Eur Respir J. 1998;12:705-715.
27. Kessler R, Massard G, Warter A, Wihlm JM, Weitzenblum E. Bronchial-pulmonary artery fistula after unilateral lung transplantation: a case report. J Heart Lung Transplant. 1997;16:674-677.
28. Brenier-Pinchart MP, Lebeau B, Devouassoux G, et al. Aspergillus and lung transplant recipients: a mycologic and molecular epidemiologic study. J Heart Lung Transplant. 1998;17:972-979.
29. Shreeniwas R, Schulman LL, Berkman YM, McGregor CC, Austin JHM. Opportunistic bronchopulmonary infections after lung transplantation: clinical and radiographic findings. Radiology. 1996;200:349-356.
30. Sole A, Morant P, Salavert M, Peman J, Morales, R Valencia Lung Transplant Group. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect. 2005;11:359-365.
31. Tazelaar HD, Baird AM, Mill M, Grimes MM, Schulman LL, Smith CR. Bronchocentric mycosis occurring in transplant recipients. Chest. 1989;96:92-95.
32. Stewart S, McNeil K, Nashef SA, Wells FC, Higenbottam TW, Wallwork J. Audit of referral and explant diagnosis in lung transplantation: a pathologic study of lungs removed for parenchymal disease. Heart Lung Transplant. 1995;14:1173-1186.
33. Ayman O, Soubani MD, Pranatharthi H, Chandrasekar MD. The clinical spectrum of pulmonary aspergillosis. Chest. 2002;121:1988-1999.
34. Sanchez JL, Kruger RM, Paranjothi S, et al. Relationship of cytomegalovirus viral load in blood to pneumonitis in lung transplant recipients. Transplantation. 2001;72:733-735.
35. Hopkins PM, Aboyoun CL, Chhajed PN, et al. Prospective analysis of 1,235 transbronchial lung biopsies in lung transplant recipients. J Heart Lung Transplant. 2002;21:1062-1067.
36. Trulock EP, Ettinger NA, Brunt EM, Pasque MK, Kaiser LR, Cooper JD. The role of transbronchial lung biopsy in the treatment of lung transplant recipients. Chest. 1992;102:1049-1054.
37. Collins J, Muller NL, Kazerooni EA, Paciocco G. CT findings of pneumonia after lung transplantation. AJR Am J Roentgenol. 2000;175:811-818.
38. Franquet T, Lee KS, Muller NL. Thin-section CT findings in 32 immunocompromised patients with cytomegalovirus pneumonia who do not have AIDS. AJR Am J Roentgenol. 2003;181:1059-1063.
39. Chemaly RF, Yen-Lieberman B, Castilla EA, et al. Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipient determined by histology and immunohistochemistry. J Clin Microbiol. 2004;42:2168-2172.
40. Humar A, Gregson D, Caliendo AM, et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation. 1999;68:1305-1311.
41. Rayes N, Seehofer D, Schmidt CA, et al. Prospective randomised trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation. Transplantation. 2001;72:881-885.
42. Senechal M, Dorent R, du Montcel ST, et al. Monitoring of human cytomegalovirus infections in heart transplant recipients by pp65 antigenemia. Clin Transplant. 2003;17:423-427.
43. Zamora MR. Cytomegalovirus and lung transplantation. Am J Transplant. 2004;4:1219-1226.
44. Westall GP, Michaelides A, Williams TJ, Snell GJ, Kotsimbos TC. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J Infect Dis. 2004;190:1076-1083.
45. Zedtwitz-Liebenstein K, Jaksch P, Bauer C, et al. Association of cytomegalovirus DNA concentration in epithelial lining fluid and symptomatic cytomegalovirus infection in lung transplant recipients. Transplantation. 2004;77:1897-1899.
46. Weinberg A, Hodges TN, Li S, Cai G, Zamora MR. Comparison of PCR, antigenemia assay, and rapid blood culture detection and prevention of cytomegalovirus disease after lung transplantation. J Clin Microbiol. 2000;38:768-772.
47. Sanchez JL, Storch GA. Multiplex quantitative, real-time PCR assay for cytomegalovirus human DNA. J Clin Microbiol. 2002;40:2381-2386.
48. Boeckh M. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy. Transpl Infect Dis. 1999;1:165-178.
49. Konoplev S, Champlin RE, Giralt S, et al. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant. 2001;27:877-881.
50. Machado CM, Dulley FL, Boas LS, et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy. Bone Marrow Transplant 2000;26:413-417.
51. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-1044.
52. Chen FE, Aubert G, Travers P, Dodi IA, Madrigal JA. HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy. Cytotherapy 2002;4:41-48.
53. Gratama JW, Cornelissen JJ. Clinical utility of tetramer-based immune monitoring in allogeneic stem cell transplantation. Bio Drugs. 2003;17:325-338.
54. Fries BC, Riddell SR, Kim HW, et al. Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation. Biol Blood Marrow Transplant. 2005;11:136-48.
55. Wendt CH. Community respiratory viruses: organ transplant recipients. Am J Med. 1997;102:31-36.
56. Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant. 2002;21:559-566.
57. Palmer SM Jr, Henshaw NG, Howell DN, Miller SE, Davis RD, Tapson VF. Community respiratory viral infection in adult lung transplant recipients. Chest. 1998;113:944-950.
58. Garbino J, Gerbase MW, Wunderli W, et al. Lower respiratory viral illnesses improved diagnosis by molecular methods and clinical impact. Am J Respir Crit Care Med. 2004;170:1197-1203.
59. Khalifah AP, Hachem RR, Chakinala MM, Schechtman KB, Patterson GA. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med. 2004;170:181-187.
60. Vilchez RA, Dauber J, Kusne S. Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection: myth or reality? Am J Transplant. 2003;3:245-249.
61. Bridges ND, Spray TL, Collins MH, et al. Adenovirus infection in the lung results in graft failure after lung transplantation. J Thorac Cardiovasc Surg. 1998;116:617-623.
62. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 Working Formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. Int J Heart Lung Transplant. 1996;15:1-15.
63. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;35:541-545.
64. Kotsimbos TC, Snell GI, Levvy B, et al. Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2005;157:269-275.
65. Glanville AR, Gencay M, Tamm M, et al. Chlamydia pneumoniae infection after lung transplantation. J Heart Lung Transplant. 2005;24:131-136.
66. Gerna G, Vitulo P, Rovida F, et al. Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients. J Med Virol. 2006;78:408-416.
67. Larcher C, Geltner C, Fischer H, Nachbaur D, Muller LC, Hemer HP. Human metapneumovirus infection in lung transplant recipients: clinical presentation and epidemiology. J Heart Lung Transplant. 2005;24:1891-1901.
68. Van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001;7:719-724.
69. Williams JV, Harris PA, Tollefson SJ, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med. 2004;350:443-450.
70. Van den Hoogen BG, van Doornum GJJ, Fockens JC, et al. Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients. J Infect Dis. 2003;188:1571-1577.
71. Sumino KC, Agapov E, Pierce RA, et al. Detection of severe human metapneumovirus infection by real-time polymerase chain reaction and histopathological assessment. J Infect Dis. 2005;192:1052-1060.
72. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998;27:1266-1277.
73. Meyers BR, Halpen M, Sheiner P, Mendelson MH, Neibart E, Miller C. Tuberculosis in liver transplant patients. Transplantation. 1994;58:301-306.
74. Korner MM, Hirata N, Tenderich G, et al. Tuberculosis in heart transplant recipients. Chest. 1997;111:365-369.
75. Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis. 2004;38:1428-1439.
76. Bravo C, Roldan J, Roman A, et al. Tuberculosis in lung transplant recipients. Transplantation. 2005;1579:59-64.
77. Novick RJ, Moreno-Cabral CE, Stinson EB, et al. Nontuberculosis mycobacterial infections in heart transplant recipients: a seventeen-year experience. J Heart Transplant. 1990;9:357-363.
78. Weinstock DM, Feinstein MB, Sepkowitz KA, Jakubowski A. High rates of infection and colonization by nontuberculous mycobacteria after allogenic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;31:1015-1021.
79. Kesten S, Chaparro C. Mycobacterial infections in lung transplant recipients. Chest. 1999;115:741-745.
80. Gordon SM, LaRosa SP, Kalmadi S, et al. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis. 1999;28:240-246.
81. Marras TK, Sanders K, Lipton JH, Messner HA, Conly J, Chan CK. Aerosolized pentamide prophylaxis for Pneumocystis pneumonia after allogeneic marrow transplantation. Transpl Infect Dis. 2002;4:66-74.
82. Tuan IZ, Dennison D, Weisdorf DJ. Pneumocystis carinii pneumonitis following bone marrow transplantation. Bone Marrow Transplant. 1992;10:267-272.
83. Khan MA, Farrag N, Butcher P. Diagnosis of Pneumocystis carinii pneumonia: immunofluorescence staining, simple PCR or nPCR. J Infect. 1999;39:77-80.
84. Olsson M, Straline K, Holmberg H. Clinical significance of nested polymerase chain reaction and immunofluorescence for detection of Pneumocystis carinii pneumonia. Clin Microbiol Infect. 2001;7:492-497.
85. Arasteh KN, Simon V, Musch R, et al. Sensitivity and specificity of indirect immunofluorescence and Grocott-technique in comparison with immunocytology (alkaline phosphate anti alkaline phosphatase = APAAP) for the diagnosis of Pneumocystis carinii in broncho-alveolar lavage (BAL). Eur J Med Res. 1998;3:559-563.
86. Brancart F, Rodriquez-Villalobos H, Fonteyne FA, Peres-Bota D, Liesnard C. Quantitive TaqMan PCR for detection of Pneumocystis jiroveci. J Microbiol Methods. 2005;61:381-387.
87. Rimek D, Kluge I, Kappe R. Evaluation of a panfungal per assay for the diagnosis of Pneumocystis carinii pneumonia (PJP) [in German]. Mycoses. 2000;43(suppl 2):37-40.
88. Pinalour S, Mootsikapun P, Pinlaor P, et al. PCR diagnosis of Pneumocystis carinii on sputum and bronchoalveolar lavage samples in immuno-compromised patients. Parasitol Res. 2004;94:213-218.
89. Alvarez-Martinez MJ, Miro JM, Vails ME, et al. Sensitivity and specificity of nested and real-time PCR for the detection of Pneumocystis jiroveci in clinical specimens. Diagn Microbiol Infect Dis. 2006;56:156-160.